title: hIgD promotes human Burkitt lymphoma Daudi cell proliferation by accelerated G1/S transition via IgD receptor activity.
abstract: The aim of the present study was to investigate the role and molecular mechanism of human IgD (hIgD) on the proliferation of human Burkitt lymphoma Daudi cells in vitro. Logarithmically growing Daudi cells were treated with hIgD for different time periods, and cell proliferation was evaluated by cell counting kit-8 (CCK-8) assay. The expressions of Daudi surface markers and IgD receptor (IgDR) as well as cell cycle and apoptosis were measured by flow cytometry analysis. Our results showed that hIgD stimulation induced proliferation and IgDR expression and reduced the apoptosis of Daudi cells. Treatment with hIgD promoted progression of the cell cycle at the G1/S transition, and this was accompanied by upregulation of c-myc, cyclin D3, and CDK6 as well as downregulation of p16 mRNA and protein levels. Moreover, hIgD treatment also upregulated the expression of tyrosine phosphorylation of 70 kDa protein (IgDR) and p-Lyn. Taken together, these results indicate that hIgD can induce Daudi cell proliferation through activating IgDR to initiate the tyrosine phosphorylation signaling cascade to accelerate the G1/S transition.
authors.affiliation: Key Laboratory of Anti-inflammatory and Immune Medicine of the Education Ministry of China, Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Institute of Clinical Pharmacology, Anhui Medical University, Meishan Road 81, Hefei, 230032, China.
authors.forename: Xing
authors.initials: X
authors.lastname: Dai
authors.affiliation: Key Laboratory of Anti-inflammatory and Immune Medicine of the Education Ministry of China, Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Institute of Clinical Pharmacology, Anhui Medical University, Meishan Road 81, Hefei, 230032, China.
authors.forename: YuJing
authors.initials: Y
authors.lastname: Wu
authors.affiliation: Key Laboratory of Anti-inflammatory and Immune Medicine of the Education Ministry of China, Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Institute of Clinical Pharmacology, Anhui Medical University, Meishan Road 81, Hefei, 230032, China.
authors.forename: XiaoYi
authors.initials: X
authors.lastname: Jia
authors.affiliation: Key Laboratory of Anti-inflammatory and Immune Medicine of the Education Ministry of China, Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Institute of Clinical Pharmacology, Anhui Medical University, Meishan Road 81, Hefei, 230032, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Chang
authors.affiliation: Key Laboratory of Anti-inflammatory and Immune Medicine of the Education Ministry of China, Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Institute of Clinical Pharmacology, Anhui Medical University, Meishan Road 81, Hefei, 230032, China.
authors.forename: HuaXun
authors.initials: H
authors.lastname: Wu
authors.affiliation: Key Laboratory of Anti-inflammatory and Immune Medicine of the Education Ministry of China, Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Institute of Clinical Pharmacology, Anhui Medical University, Meishan Road 81, Hefei, 230032, China.
authors.forename: Chun
authors.initials: C
authors.lastname: Wang
authors.affiliation: Key Laboratory of Anti-inflammatory and Immune Medicine of the Education Ministry of China, Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Institute of Clinical Pharmacology, Anhui Medical University, Meishan Road 81, Hefei, 230032, China.
authors.forename: HengShi
authors.initials: H
authors.lastname: Chen
authors.affiliation: Key Laboratory of Anti-inflammatory and Immune Medicine of the Education Ministry of China, Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Institute of Clinical Pharmacology, Anhui Medical University, Meishan Road 81, Hefei, 230032, China.
authors.forename: WenSheng
authors.initials: W
authors.lastname: Chen
authors.affiliation: Key Laboratory of Anti-inflammatory and Immune Medicine of the Education Ministry of China, Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Institute of Clinical Pharmacology, Anhui Medical University, Meishan Road 81, Hefei, 230032, China.
authors.forename: Qiong
authors.initials: Q
authors.lastname: Huang
authors.affiliation: Key Laboratory of Anti-inflammatory and Immune Medicine of the Education Ministry of China, Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Institute of Clinical Pharmacology, Anhui Medical University, Meishan Road 81, Hefei, 230032, China. wwei@ahmu.edu.cn.
authors.forename: Wei
authors.initials: W
authors.lastname: Wei
mesh_terms: D002051:Burkitt Lymphoma / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D056743:Cyclin D3 / Q000378:metabolism; D051361:Cyclin-Dependent Kinase 6 / Q000378:metabolism; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000235:genetics / Q000378:metabolism; D059585:G1 Phase Cell Cycle Checkpoints; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007072:Immunoglobulin D / Q000378:metabolism*; D007167:Immunotherapy / Q000379:methods*; D058990:Molecular Targeted Therapy; D010766:Phosphorylation; D016271:Proto-Oncogene Proteins c-myc / Q000378:metabolism; D011961:Receptors, Fc / Q000378:metabolism*; D015398:Signal Transduction
chemical_list: C000614131:CDKN2A protein, human; D056743:Cyclin D3; D019941:Cyclin-Dependent Kinase Inhibitor p16; D007072:Immunoglobulin D; C489427:MYC protein, human; D016271:Proto-Oncogene Proteins c-myc; D011961:Receptors, Fc; C050855:immunoglobulin D receptor; C495911:CDK6 protein, human; D051361:Cyclin-Dependent Kinase 6
keywords: Burkitt lymphoma; G1/S checkpoint; IgD receptor; Proliferation; Tyrosine phosphorylation